Adocia was founded in December 2005 by Gérard Soula and his two sons, Olivier and Rémi.
These three highly skilled scientists each have a PhD degree in polymer science and they have a strong track record in protein delivery. Based on this expertise, they have designed innovative protein formulations for regenerative medicine and chronic disease: BioChaperone®, a “Molecular Delivery System of Therapeutic Proteins”.
PhD, MBA – President and CEO
Gérard Soula has a PhD in Organic chemistry and has an MBA from IAE (Aix Marseille).
He founded Flamel Technologies (in 1990), a biotech company specialized in Drug Delivery and listed on Nasdaq. He was the CEO and Director of Research until June 2005. When he left, Flamel had 250 employees, $100M cash in bank and a market capitalization of $500M. Flamel Technologies’ success is based on the performances of its platforms, Micropump and Medusa.
Furthermore, Gérard Soula has a strong track record in negotiating license agreements in innovating technologies with big pharma groups (Novo Nordisk, Bristol Myers Squibb, GlaxoSmithKline etc). He is the co-author of more than 120 patents.
PhD, MBA – Deputy General Manager – R&D Director
Olivier Soula has a PhD in polymer science, graduated from ENSIC Mulhouse, and has an MBA from IAE, Lyon.
He worked for 8 years at Flamel Technologies as Director of the Nanotechnologies department. He led the development of Medusa, a prolonged release platform of therapeutic proteins and successfully conducted clinical trials for three of those projects.
Olivier is co-author of nearly 40 patents relating to protein delivery. He has worked for 16 years on insulin formulation.
PhD, MBA – Business Development and Legal
Rémi Soula has a PhD in polymer science. He did his Post-Doc at the Max Planck Institute in Postdam and has an MBA from HEC Paris. Rémi spent 3 years at Flamel Technologies as senior manager in Polymer Synthesis.
Dr Rémi Soula, Director of Business Development and Legal, contributed with talent and energy to develop the Company during his 14 years tenure. As of October 18, 2019, he pursues other professional endeavors.
Dr Rémi Soula is the co-author of more than 30 patents and 6 scientific publications.